Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.

The lancet. Diabetes & endocrinology·2025

Same author

Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.

JAMA·2025

Same author

Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis.

The lancet. Diabetes & endocrinology·2023

Same author

Worldwide Consensus on Thyroid Eye Disease? What Is In a Name?

Thyroid : official journal of the American Thyroid Association·2022

Same author

Hypothyroid Symptoms Throughout Pregnancy Are Predominantly Associated with Thyroxine and Not with Thyrotropin Concentrations.

Thyroid : official journal of the American Thyroid Association·2022

Same author

<i>European Thyroid Journal:</i> Looking Backwards and Forwards.

European thyroid journal·2021

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Amiodarone and thyroid.

Silvia A Eskes¹, Wilmar M Wiersinga

¹Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, The Netherlands.

Best Practice & Research. Clinical Endocrinology & Metabolism

|November 28, 2009

Summary

This summary is machine-generated.

Thyroid dysfunction is common during amiodarone (AM) treatment. Early monitoring is key, as amiodarone-induced thyrotoxicosis (AIT) has subtypes requiring different treatments and carries cardiovascular risks.

Related Experiment Videos

Last Updated: Jun 18, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Area of Science:

Endocrinology
Cardiology
Pharmacology

Background:

Amiodarone (AM) is an effective antiarrhythmic drug but frequently causes thyroid dysfunction.
Thyroid monitoring is crucial due to the potential for amiodarone-induced hypothyroidism and thyrotoxicosis (AIT).

Purpose of the Study:

To review the assessment, management, and outcomes of thyroid dysfunction associated with amiodarone (AM) treatment.
To differentiate between the two main types of AIT and discuss treatment strategies.

Main Methods:

Review of existing literature on amiodarone-induced thyroid dysfunction.
Analysis of clinical presentation, diagnostic criteria, and treatment outcomes for AIT types 1 and 2.

Main Results:

Amiodarone-induced hypothyroidism often occurs early, particularly in iodine-sufficient areas and females with TPO-Ab.
Amiodarone-induced thyrotoxicosis (AIT) can occur anytime, more in iodine-deficient regions and males, with distinct type 1 and type 2 presentations.
AIT is linked to increased cardiovascular adverse events, including arrhythmias.

Conclusions:

Pre-treatment TSH and TPO-Ab assessment is recommended; periodic TSH monitoring during AM treatment has limitations.
Distinguishing AIT types is critical for appropriate management (e.g., potassium perchlorate/thionamides for type 1, prednisone for type 2).
Further research is needed on managing AIT, especially regarding AM continuation and restarting the drug.